GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 43
- Registration Number
- NCT04915755
- Locations
- 🇬🇧
GSK Investigational Site, Wigan., United Kingdom
Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE)
- Conditions
- Interventions
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2022-12-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 65
- Registration Number
- NCT04908865
- Locations
- 🇨🇳
GSK Investigational Site, Xi'an, China
Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
- Conditions
- Interventions
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26668
- Registration Number
- NCT04886596
- Locations
- 🇬🇧
GSK Investigational Site, Witney, United Kingdom
A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults
- First Posted Date
- 2021-05-13
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1429
- Registration Number
- NCT04886154
- Locations
- 🇹🇷
GSK Investigational Site, Kocaeli, Turkey
Bioequivalence Study Between Capoten Versus Captopril Reference Product in Healthy Adult Participants Under Fasting Conditions
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT04878315
Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6138
- Registration Number
- NCT04869982
- Locations
- 🇨🇳
GSK Investigational Site, Shanghai, China
Investigation of Chronic Obstructive Pulmonary Disease (COPD) Phenotypes and Endotypes in China
- Conditions
- Interventions
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2000
- Registration Number
- NCT04853225
- Locations
- 🇨🇳
GSK Investigational Site, Shenzhen, China
Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China
- Conditions
- Interventions
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1507
- Registration Number
- NCT04853238
- Locations
- 🇨🇳
GSK Investigational Site, Zhengzhou, China
A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above
- Conditions
- Interventions
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 976
- Registration Number
- NCT04841577
- Locations
- 🇿🇦
GSK Investigational Site, Middelburg, Mpumalanga, South Africa
A Comparison of Critical Errors, Overall Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers (DPIs) in Adult Participants With Asthma
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 114
- Registration Number
- NCT04813354
- Locations
- 🇳🇱
GSK Investigational Site, Rotterdam, Netherlands